Yale Research Video, page-8

The current management group, right from the time of their commencement with the company - understand the massive potential here, and what is at stake with Cantrixil. (in my view)

Indeed this breakthrough cancer drug is the very reason our high profile management group joined the company. The work of Dr Mor, which they understand to a much greater level than shareholders, is the prime reason for confidence in the drug. The model is unique, extremely robust and value conclusive. (my view)

It would follow than......... if I am correct and the stakes are indeed very high - this is the reason that previous management were moved on. After a settling in period "they" had the power to remove certain people from the company and thats what happened. The perception right or wrong, is that a former $10m PA Eli Elly and others new to the company, could do a better job.

I have significant new information, which is best presented next time the company has a share price run. So back to my theory.....if that is the reason why the previous CEO left, why are we at just over US$20m cap, when our deputy chairman earn' t that amount in 2 years.

Why are these people with the company, if we are not sitting on a major cancer breakthrough ? Why does the market not see what is so plainly apparent, given the role taken up by a big Pharma executive in our company.

Well I can see clearly what lays ahead for shareholders. Excitement such that you will see once only.